Therapy of recurrent and refractory multiple Myeloma Isatuximab improves progression-free Survival

被引：0
|
作者：
Ruedesheim, Sabine M.
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / 7-8期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：397 / 397
页数：1
相关论文
共 50 条
  • [41] Long-time progression-free survival in relapsed, refractory multiple myeloma with the oral ixazomib-lenalidomide-dexamethasone regime
    Hardi, Apor
    Varga, Gergely
    Nagy, Zsolt
    Kosztolanyi, Szabolcs
    Varoczy, Laszlo
    Plander, Mark
    Schneider, Tamas
    Demeter, Judit
    Alizadeh, Hussain
    Illes, Arpad
    Masszi, Tamas
    Mikala, Gabor
    [J]. ORVOSI HETILAP, 2021, 162 (36) : 1451 - 1458
  • [42] Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients
    Rebmann, Vera
    Schuett, Philipp
    Brandhorst, Dieter
    Opalka, Bertram
    Moritz, Thomas
    Nowrousian, Mohammad Reza
    Grosse-Wilde, Hans
    [J]. CLINICAL IMMUNOLOGY, 2007, 123 (01) : 114 - 120
  • [43] Immunoglobulin Recovery after ASCT for Patients with Multiple Myeloma: Impact on Overall Survival and Progression-Free Survival
    Jimenez-Zepeda, Victor
    Duggan, Peter
    Neri, Paola
    Chaudhry, Ahsan
    Tay, Jason
    Bahlis, Nizar J.
    [J]. BLOOD, 2016, 128 (22)
  • [44] Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients
    Avet-Loiseau, Herve
    Bahlis, Nizar J.
    Chng, Wee-Joo
    Masszi, Tamas
    Viterbo, Luisa
    Pour, Ludek
    Ganly, Peter
    Palumbo, Antonio
    Cavo, Michele
    Langer, Christian
    Pluta, Andrzej
    Nagler, Arnon
    Kumar, Shaji
    Ben-Yehuda, Dina
    Rajkumar, S. Vincent
    San-Miguel, Jesus
    Berg, Deborah
    Lin, Jianchang
    van de Velde, Helgi
    Esseltine, Dixie-Lee
    di Bacco, Alessandra
    Moreau, Philippe
    Richardson, Paul G.
    [J]. BLOOD, 2017, 130 (24) : 2610 - 2618
  • [45] Morbid Progression Is Common Among Patients with Multiple Myeloma and Is Associated with Shortened Overall Survival: Validation of the Progression-Free Survival Endpoint
    Rosenberg, Aaron Seth
    Facon, Thierry
    Abouzaid, Safiya
    Srinivasan, Shankar
    Chung, Weiyuan
    Parikh, Kejal
    Tuscano, Joseph
    [J]. BLOOD, 2017, 130
  • [46] High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma
    Miller, A.
    Asmann, Y.
    Cattaneo, L.
    Braggio, E.
    Keats, J.
    Auclair, D.
    Lonial, S.
    Russell, S. J.
    Stewart, A. K.
    [J]. BLOOD CANCER JOURNAL, 2017, 7 : e612 - e612
  • [47] Levels of Uninvolved Immunoglobulin Predict Clinical Status and Progression-Free Survival for Multiple Myeloma Patients
    Harutyunyan, Nika M.
    Vardanyan, Suzie
    Ghermezi, Michael
    Gottlieb, Jillian
    Berenson, Ariana
    Andreu-Vieyra, Claudia
    Tang, George
    Sanchez, Eric
    Li, Mingjie
    Wang, Cathy
    Ben-Zvi, Joseph
    Garzio, Gigi
    Chen, Haiming
    Finlay, Judith
    Berenson, James R.
    [J]. BLOOD, 2014, 124 (21)
  • [48] Use of depth of response to predict progression-free survival in relapsed or refractory multiple myeloma: Evaluation of results from 102 clinical trials
    Mangal, Naveen
    Salem, Ahmed Hamed
    Menon, Rajeev M.
    Freise, Kevin J.
    [J]. HEMATOLOGICAL ONCOLOGY, 2018, 36 (03) : 547 - 553
  • [49] High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma
    A Miller
    Y Asmann
    L Cattaneo
    E Braggio
    J Keats
    D Auclair
    S Lonial
    S J Russell
    A K Stewart
    [J]. Blood Cancer Journal, 2017, 7 : e612 - e612
  • [50] AN ONGOING MULTINATIONAL OBSERVATIONAL STUDY IN MULTIPLE MYELOMA (PREAMBLE): PRELIMINARY REPORT ON PROGRESSION-FREE SURVIVAL
    Kuter, D.
    Cook, G.
    Goldschmidt, H.
    Cella, D.
    Zyczynski, T.
    Davis, C.
    Popov, S.
    Vij, R.
    [J]. HAEMATOLOGICA, 2016, 101 : 520 - 520
12345